• Ascentage Pharma granted 3,664,428 RSUs across its 2021 and 2022 RSU schemes, tied to 3,664,428 shares, on June 29, 2026.
• The 2022 RSU grant totaled 3,223,685 RSUs, including 138,052 RSUs to directors, with vesting running through June 29, 2030.
• A separate 2021 RSU grant covered 440,743 RSUs to 453 employees, set to vest on the grant date.
• Ascentage also granted 690,045 share options to 30 grantees, exercisable at HK$ 33.62 per share, with a 10-year exercise term.
• Options for directors vest monthly through June 29, 2027; remaining options vest annually through June 29, 2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-073699), on June 30, 2026, and is solely responsible for the information contained therein.